Perkins Capital Management’s Bionano Genomics BNGO Stock Holding History

Perkins Capital Management’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-783	Closed	-$306K	–	102
2020 Q3	$306K	Buy	+783	New	+$304K	0.28%	70
2019 Q1	–	Sell	-56	Closed	-$176K	–	129
2018 Q4	$176K	Sell	56 -26	-32%	-$104K	0.14%	107
2018 Q3	$390K	Buy	+82	New	+$350K	0.23%	102

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Perkins Capital Management's BNGO Position: Q4 2020 in Review

Perkins Capital Management sold out of Bionano Genomics (BNGO) in Q4 2020, closing a stake of 783 shares — an estimated $306K sold.

Perkins Capital Management first reported a position in BNGO in Q3 2018 and held it in 3 quarters. The position peaked at $390K in Q3 2018. 48 funds tracked by Wall St. Rank hold BNGO as of Q4 2020.

Perkins Capital Management reported no remaining Bionano Genomics position as of Q4 2020 after selling out during the quarter.
Perkins Capital Management sold 783 Bionano Genomics shares in Q4 2020, an estimated $306K.
Perkins Capital Management first reported a position in Bionano Genomics in Q3 2018 and held it in 3 quarters.
Perkins Capital Management's Bionano Genomics position peaked at $390K in Q3 2018.
48 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2020.

Based on Perkins Capital Management's 13F filing for Q4 2020, filed 9 Feb 2021.